Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for inducing an immune response comprising the step of applying to the unbroken surface of the skin a composition comprising a particulate antigen and a pharmaceutically acceptable carrier, wherein said particulate antigen is of diameter from about 50 to 200 nm and said composition does not ~~comprise~~ contain an adjuvant. ~~cholera toxin or cholera toxoid protein.~~

Claim 2 (previously amended): The method of claim 1 wherein the particulate antigen is an inactivated virus particle.

Claims 3 and 4 (previously canceled)

Claim 5 (previously amended): The method of claim 2 wherein the particulate antigen is about 100 nm in diameter.

Claim 6 (canceled)

Claim 7 (previously amended): The method of claim 2 wherein the inactivated virus particle is selected from the group consisting of an orthomyxovirus particle and a paramyxovirus particle.

Claim 8 (original): The method of claim 7 wherein the inactivated virus particle is an influenza virus particle.

Claim 9 (previously amended): The method of claim 1 wherein the particulate antigen is a virus-like particle.

Claim 10 (previously amended): The method of claim 9 wherein the virus-like particle comprises hemagglutinin.

Claim 11 (previously amended): The method of claim 10 wherein the hemagglutinin is incorporated into the particle by mixed infection with an orthomyxovirus or a paramyxovirus.

Claim 12 (previously amended): The method of claim 2 wherein the particulate antigen comprises mixed inactivated virus particles comprising hemagglutinin which is heterologous to the virus.

Claim 13 (previously amended): The method of claim 12 wherein the hemagglutinin is a recombinant hemagglutinin of influenza virus or parainfluenza virus.

Claim 14 (previously amended): The method of claim 12 where the hemagglutinin is incorporated through mixed infection with an orthomyxovirus or a paramyxovirus.

Claim 15 (previously amended): The method of claim 12 wherein the virus particle is a noninfectious particle of parainfluenza virus, hepatitis C virus, hepatitis virus B, measles virus, vaccinia virus, herpes virus or respiratory syncytium virus.

Claim 16 (original): The method of claim 2 wherein the virus particle has been inactivated by chemical treatment, ultraviolet irradiation, heat treatment or psoralen treatment.

Claim 17 (original): The method of claim 16 wherein the chemical treatment is formalin treatment.

Claim 18 (currently amended): A method for inducing an immune response comprising the step of applying to the unbroken surface of the skin a composition comprising a particulate antigen of diameter from about 5 to 200 nm and a pharmaceutically acceptable carrier, wherein said particulate antigen is an inactivated or attenuated virus particle and said composition does not contain an adjuvant. ~~cholera toxin or cholera toxoid protein.~~

Claims 19 and 20 (canceled)

Claim 21 (currently amended): The method of claim 18 wherein the inactivated or attenuated virus particle contains hemagglutinin.

Claim 22 (original): The method of claim 21 wherein the hemagglutinin is derived from an orthomyxovirus or a paramyxovirus.

Claim 23 (original): The method of claim 22 wherein the hemagglutinin is derived from influenza virus or a parainfluenza virus.

Claim 24 (new): A method for inducing an immune response comprising the step of applying to the unbroken surface of the skin a composition consisting essentially of a particulate antigen and a pharmaceutically acceptable carrier, wherein said particulate antigen is an inactivated influenza virus particle.

Claim 25 (new) The method of claim 24 wherein the influenza virus is inactivated with formalin.